Stoke Therapeutics (STOK) CSO Thomas McCauley files initial insider report

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. reports that Thomas McCauley, its Chief Scientific Officer, is an executive officer but not a director or 10% owner. This is an initial statement of insider status and, in the data provided, does not list any specific stock transactions or derivative positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/17/2026 - 04:33 PM Accepted by SEC EDGAR 07/17/2026 - 04:33 PM Learn about SEC filing dates

FAQ

What does the latest insider report for STOK disclose about Thomas McCauley?

The report identifies Thomas McCauley as an officer of Stoke Therapeutics with the title Chief Scientific Officer. It serves as an initial insider status statement and, in the available data, does not list any stock trades or option positions.

Does the Thomas McCauley Form 3 for STOK show any stock purchases or sales?

No, the insider report shows no reported stock purchases or sales by Thomas McCauley. Transaction counts, including buy, sell, exercise, gift, and tax withholding, are all listed as zero in the summarized data provided.

What is Thomas McCauley’s role at Stoke Therapeutics (STOK) in this insider filing?

Thomas McCauley is reported as an officer of Stoke Therapeutics with the title Chief Scientific Officer. He is not classified as a director or a 10% beneficial owner in this initial insider ownership statement.

Are any derivative securities or options reported for Thomas McCauley in the STOK Form 3?

No derivative securities are listed for Thomas McCauley in the data provided. The derivativeSummary is empty and the summarized counts show no option exercises or other derivative transactions reported in this initial statement.

Does the STOK insider report indicate use of a Rule 10b5-1 trading plan by Thomas McCauley?

The data shows the Rule 10b5-1 plan indicator as null, meaning no plan status is specified here. With no transactions reported, there is no indication that any trades were made under a trading plan in this report.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

McCauley Thomas

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/13/2026

3. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jonathan Allan, Attorney-in-Fact	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)